Genmab Competitive Intelligence & Landscape

Genmab (genmab.com) is an international biotechnology company dedicated to enhancing patients' lives through pioneering and differentiated antibody therapeutics [source]. The company focuses on inventing next-generation antibody technology platforms and leveraging translational research to develop innovative solutions [source].

Founded 25 years ago, Genmab has evolved from a small group of researchers into a thriving organization [source]. The company's headquarters are located in Valby, Denmark [source].

Genmab is a dual-listed company, with shares traded on the Copenhagen stock exchange in Denmark and on NASDAQ Global Select Market in the US [source].

Genmab's core mission is driven by an

Genmab (genmab.com) is an international biotechnology company that specializes in developing antibody therapeutics for cancer and other serious diseases. Their core purpose is to improve patient lives through innovative and differentiated antibody therapeutics [https://www.genmab.com/]. The company has a proprietary pipeline that includes investigational medicines in clinical development, as well as in-house and partnered pre-clinical programs [https://www.genmab.com/antibody-science/pipeline]. Recent developments include gaining additional proprietary technology platforms, such as DuoHexaBody®, and new antibody-drug conjugate (ADC) technology from ProfoundBio [https://ir.genmab.com/static-files/7b4cfa98-94f5-49f5-b08a-8631759dd23e].

Genmab's approach to pricing and product access is guided by ensuring timely access for patients, regardless of their socioeconomic or insurance status [https://ir.genmab.com/static-files/1a422c1a-382d-4c62-921a-1733164cf253]. They aim for the price of their medicines to reflect the transformational potential of their science, its benefits to healthcare systems and society, and their ability to invest in future breakthrough science [https://ir.genmab.com/static-files/1a422c1a-382d-4c62-921a-1733164cf253]. The company emphasizes that patient access and affordability are key considerations in their strategy [https://ir.genmab.com/static-files/7b4cfa98-94f5-49f5-b08a-8631759dd23e].

While specific pricing plans or tiers for individual products are not publicly detailed, Genmab does offer a Managed Access Program for certain medicines, and the criteria for considering requests are available on their website [https://www.genmab.com/healthcare-professionals/managed-access-program]. The pricing of their products, and any future product candidates, is contingent upon marketing approval [https://ir.genmab.com/static-files/c1fb13fb-65c5-486a-b744-d5d30869af2f]. The company's financial performance shows significant revenue, with $1,640 million for the first half of 2025, compared to $1,382 million for the first half of 2024, indicating continued investment in their pipeline and market presence [https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-half-2025/].

Genmab's product portfolio includes medicines developed in collaboration with strategic partners, such as EPKINLY® / TEPKINLY® (epcoritamab) with AbbVie Inc. and Tivdak® (tisotumab vedotin) with Pfizer Inc., alongside wholly Genmab-owned products [https://ir.genmab.com/static-files/78495c53-291f-4861-8e48-f3230c45b9eb]. The company's focus remains on translating innovative science into medicines that create value and have a meaningful impact on patients and health systems [https://ir.genmab.com/static-files/7b4cfa98-94f5-49f5-b08a-8631759dd23e].

Genmab (genmab.com) actively recruits for a range of specialized roles, reflecting its commitment as an innovation powerhouse in antibody therapeutics. The company emphasizes an "extra[not]ordinary®" career, encouraging individuals to make a profound difference within one of the world's top companies solely dedicated to this field [https://careers.genmab.com/global/en/home]. This ongoing recruitment underscores a strategy focused on continuous growth and advancement in biotech innovation.

Recent hiring trends at Genmab indicate a strong focus on scientific and medical expertise. Notable job openings span critical areas such as Research & Discovery [https://careers.genmab.com/global/en/c/research-discovery-jobs], Development [https://careers.genmab.com/global/en/c/development-jobs], Development Operations [https://careers.genmab.com/global/en/c/development-operations-jobs], and Medical Affairs [https://careers.genmab.com/global/en/c/medical-affairs-jobs]. The consistent availability of positions across these departments signals Genmab's dedication to expanding its capabilities from early research through clinical development and medical support.

Genmab's hiring patterns suggest a sustained period of expansion, with no publicly available information indicating recent layoffs. The company maintains a dedicated careers page [https://careers.genmab.com] as the exclusive source for legitimate job opportunities, emphasizing a transparent and direct recruitment process. This approach highlights Genmab's intent to attract and retain top talent, supporting its long-term strategic goals in the highly competitive biotechnology sector.

In terms of financial performance, Genmab demonstrated robust growth in 2025, reporting approximately $3.6 billion in revenue for the twelve months ended September 30, 2025, with royalty revenues accounting for $2.9 billion of this total [https://ir.genmab.com/node/48596/html]. The company also achieved $1.5 billion in net income and $1.5 billion in Adjusted EBITDA during the same period [https://ir.genmab.com/node/48596/html]. Earlier in 2025, Genmab's revenue increased by 21% compared to the first nine months of 2024, reaching $2,662 million [https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-nine-months-2025/]. The company's annual reports, providing comprehensive financial data, are accessible through its investor relations section [https://www.genmab.com/investor-relations/annual-report].

A significant factor in Genmab's financial health is the performance of its partnered products. For instance, net sales of DARZALEX® by J&J reached $14,351 million in 2025, an increase from $11,670 million in 2024 [https://ir.genmab.com/news-releases/news-release-details/genmab-publishes-2025-annual-report/]. This strong performance contributes to Genmab's royalty revenues and overall financial stability, as detailed in their published annual reports for both 2024 and 2025 [https://ir.genmab.com/news-releases/news-release-details/genmab-publishes-2024-annual-report/], [https://ir.genmab.com/news-releases/news-release-details/genmab-publishes-2025-annual-report/].

Regarding M&A activity, Genmab has announced a proposed acquisition of Merus N.V. (Merus) [https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-nine-months-2025/]. This strategic move indicates Genmab's continued efforts to expand its portfolio and market presence through inorganic growth, alongside its strong internal pipeline development.

Genmab actively participates in a variety of conferences, both presenting and attending, to highlight its advancements in oncology and engage with the healthcare community. For instance, Genmab's CEO, Jan van de Winkel, Ph.D., presented company updates at both the 43rd Annual J.P. Morgan Healthcare Conference in January 2025 and the 44th Annual J.P. Morgan Healthcare Conference in January 2026 [ir.genmab.com/news-releases/news-release-details/genmab-present-43rd-annual-jp-morgan-healthcare-conference, ir.genmab.com/news-releases/news-release-details/genmab-present-44th-annual-jp-morgan-healthcare-conference]. Additionally, the company is set to showcase advances in its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress [ir.genmab.com/genmab-news].

Genmab also participates in key industry events through fireside chats and presentations. Its Chief Financial Officer, Anthony Pagano, participated in a fireside chat at the 46th Goldman Sachs Annual Global Healthcare Conference in May 2025 [ir.genmab.com/news-releases/news-release-details/genmab-participate-fireside-chat-46th-goldman-sachs-annual]. Similarly, Chief Development Officer Judith Klimovsky engaged in a fireside chat at the 2025 Jefferies Global Health Care Conference in June 2025 [ir.genmab.com/news-releases/news-release-details/genmab-participate-fireside-chat-2025-jefferies-global-health]. The company also presented new research at the 2025 ASCO Annual Meeting and hosted a virtual investor update to review the data presented [ir.genmab.com/news-releases/news-release-details/genmab-highlight-new-data-evaluating-late-stage-oncology].

Financial updates and strategic insights are shared through dedicated events, including conference calls and virtual meetings.

Genmab held a conference call to discuss its Q1 2026 financial results on May 7, 2026, with registration required for participants [ir.genmab.com/events-presentations/, ir.genmab.com/financial-calendar]. In December 2024, Genmab hosted a virtual R&D Update and ASH Data Review Meeting, accessible via live webcast [ir.genmab.com/news-releases/news-release-details/genmab-hold-2024-rd-update-and-ash-data-review-meeting]. The company's Annual General Meeting for 2026 is scheduled for Thursday, March 19 [ir.genmab.com/events-presentations/].

Beyond investor and medical conferences, Genmab engages in events relevant to talent acquisition. The company has an upcoming Annual Conference and Career Expo scheduled for Thursday, September 24, to Friday, September 25, 2026, in Los Angeles, California, demonstrating its commitment to connecting with future talent and industry professionals [careers.genmab.com/global/en/events].